• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of COVID-19 booster dose: is the juice worth the squeeze?

作者信息

Madhi Shabir A, Izu Alane

机构信息

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa; Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.

出版信息

Lancet Infect Dis. 2023 Oct;23(10):1097-1099. doi: 10.1016/S1473-3099(23)00296-7. Epub 2023 Jun 20.

DOI:10.1016/S1473-3099(23)00296-7
PMID:37352876
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10281642/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a63f/10281642/60d9ac79ba55/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a63f/10281642/60d9ac79ba55/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a63f/10281642/60d9ac79ba55/fx1_lrg.jpg

相似文献

1
Safety of COVID-19 booster dose: is the juice worth the squeeze?新冠病毒加强针的安全性：费力是否值得？
Lancet Infect Dis. 2023 Oct;23(10):1097-1099. doi: 10.1016/S1473-3099(23)00296-7. Epub 2023 Jun 20.
2
Booster doses of COVID-19 vaccines.新冠疫苗加强针
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-188.
3
COVID-19 update:Booster dose of the Pfizer vaccine for children 5-11 years old.新冠疫情最新消息：为5至11岁儿童接种辉瑞疫苗加强针。
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94.
4
What a second booster dose of mRNA COVID-19 vaccines tells us.新冠病毒mRNA疫苗的第二剂加强针告诉了我们什么。
Lancet Infect Dis. 2022 Aug;22(8):1092-1093. doi: 10.1016/S1473-3099(22)00282-1. Epub 2022 May 9.
5
In brief: Booster doses of mRNA-based COVID-19 vaccines for all adults.简而言之：为所有成年人接种基于mRNA的新冠病毒疫苗加强针。
Med Lett Drugs Ther. 2021 Dec 27;63(1640):201-202.
6
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.COVID-19 疫苗加强针接种后的安全性监测-美国，2021 年 9 月 22 日-2022 年 2 月 6 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1.
7
COVID-19 updates: Second booster vaccine dose for older and immunocompromised persons.新冠疫情最新消息：为老年人和免疫功能低下者接种第二剂加强针疫苗。
Med Lett Drugs Ther. 2022 Apr 18;64(1648):63-64.
8
Booster shots for COVID-19-the debate continues.新冠病毒疫苗加强针——争论仍在继续。
Lancet Infect Dis. 2021 Oct;21(10):1359-1360. doi: 10.1016/S1473-3099(21)00574-0.
9
Immunogenicity and safety of different platforms of COVID-19 vaccines given as a third (booster) dose in healthy adults.在健康成年人中作为第三剂（加强剂）接种的不同平台新冠疫苗的免疫原性和安全性。
J Med Virol. 2022 Sep;94(9):4047-4052. doi: 10.1002/jmv.27836. Epub 2022 May 16.
10
Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots.既往感染过新冠病毒后的疫苗接种：对剂量节省和加强针的影响。
EBioMedicine. 2021 Oct;72:103586. doi: 10.1016/j.ebiom.2021.103586. Epub 2021 Sep 15.

引用本文的文献

1
Incidence and Nature of Short-Term Adverse Events following COVID-19 Second Boosters: Insights from Taiwan's Universal Vaccination Strategy.新冠病毒二次加强针接种后短期不良事件的发生率及性质：来自台湾全民疫苗接种策略的见解
Vaccines (Basel). 2024 Jan 31;12(2):149. doi: 10.3390/vaccines12020149.

本文引用的文献

1
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.在以色列高危人群中使用单价和双价 BNT162b2 mRNA COVID-19 疫苗加强针的安全性：一项大规模、回顾性、自身对照病例系列研究。
Lancet Infect Dis. 2023 Oct;23(10):1130-1142. doi: 10.1016/S1473-3099(23)00207-4. Epub 2023 Jun 20.
2
Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study.广泛感染奥密克戎（BA.1）主导后，南非豪登省诱导免疫后严重和致命 COVID-19 的持续低发生率：一项观察性研究。
Viruses. 2023 Feb 21;15(3):597. doi: 10.3390/v15030597.
3
The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.具有免疫逃逸特性的新冠病毒奥密克戎亚变体迅速崛起：XBB.1.5和BQ.1.1亚变体。
MedComm (2020). 2023 Mar 15;4(2):e239. doi: 10.1002/mco2.239. eCollection 2023 Apr.
4
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.先前感染 SARS-CoV-2 和混合免疫对奥密克戎变异株和重症疾病的保护效力：系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18.
5
Global Distribution, Dispersal Patterns, and Trend of Several Omicron Subvariants of SARS-CoV-2 across the Globe.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）几种奥密克戎亚变体在全球的分布、传播模式及趋势
Trop Med Infect Dis. 2022 Nov 12;7(11):373. doi: 10.3390/tropicalmed7110373.
6
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.第二剂 BNT162b2 疫苗对 60 岁以上成年人因 COVID-19 住院和死亡的有效性。
Nat Med. 2022 Jul;28(7):1486-1490. doi: 10.1038/s41591-022-01832-0. Epub 2022 Apr 25.
7
Epidemiological designs for vaccine safety assessment: methods and pitfalls.疫苗安全性评估的流行病学设计：方法与陷阱
Biologicals. 2012 Sep;40(5):389-92. doi: 10.1016/j.biologicals.2011.08.010. Epub 2011 Oct 8.